Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.07 ^USD	+2.48%		+2.99%	-45.95%

Apr. 04	Top Premarket Gainers	MT
Mar. 19	H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating	MT

Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 15, 2024 at 04:06 pm EDT

Acurx Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 14.58 million compared to USD 12.09 million a year ago. Basic loss per share from continuing operations was USD 1.15 compared to USD 1.12 a year ago.

Latest news about Acurx Pharmaceuticals, Inc.

Top Premarket Gainers	Apr. 04	MT
H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating	Mar. 19	MT
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	Mar. 19	MT
US Futures Trend Lower in Tuesday's Premarket as Investors Await Start of 2-Day Fed Meeting	Mar. 19	MT
Transcript : Acurx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 18, 2024	Mar. 18
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Acurx Pharmaceuticals, Inc. Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2B Clinical Trial in Cdi Patients	Jan. 29	CI
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients	Jan. 17	CI
Transcript : Acurx Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM	Jan. 11
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $14 From $13, Keeps Buy Rating	Dec. 15	MT
Acurx Pharmaceuticals, Inc. Announces Positive Phase 2B Results Showing 100% of Patients Who Has Clinical Cure with Ibezapolstat Also Has Sustained Clinical Cure	Dec. 11	CI
Transcript : Acurx Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Acurx Reports 96% Clinical Cure Rate in Phase 2 Trial of Ibezapolstat in C. Difficile Infection; Shares Fall	Nov. 02	MT
Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection	Nov. 02	CI
Maxim Raises Price Target on Acurx Pharmaceuticals to $10 From $7, Keeps Buy Rating	23-10-11	MT
Acurx Pharmaceuticals, Inc. Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection	23-10-02	CI
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $13 From $14, Keeps Buy Rating	23-08-15	MT
Transcript : Acurx Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Transcript : Acurx Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 12, 2023	23-05-12
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Acurx Pharmaceuticals, Inc. Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference	23-04-19	CI
Fmw Media's Business Tv Show New to the Street Signs Acurx Pharmaceuticals, Inc. to Additional Six-Month Media Contract with Iconic Billboard Ads and Commercial Support	23-03-23	CI
Transcript : Acurx Pharmaceuticals, Inc., Q4 2022 Earnings Call, Mar 16, 2023	23-03-16

Chart Acurx Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - European Society of Clinical Microbiology and Infectious Diseases Congress - Poster #P2327

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.07 USD

Average target price

11.45 USD

Spread / Average Target

+453.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACURX PHARMACEUTICALS, INC.	-45.95%	32.62M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research